Technology Bundle ID

Caspase Inhibitors Useful for the Study of Autoimmune or Inflammatory Diseases

Linked ID
Lead Inventors
Craig Thomas (NCATS)
Matthew Boxer (NCATS)
Development Status
Early stage
Therapeutic Areas
Novel and potent caspase 1 inhibitors are available for licensing. In particular, this technology discloses potent and selective caspase 1 inhibitors that target the active site of the enzyme. Caspase 1 is known to play a pro-inflammatory role in numerous autoimmune and inflammatory diseases and therefore represents an excellent target for treatment of a broad range of diseases, including but not limited to Huntington's, amyotrophic lateral sclerosis, ischemia, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, and sepsis. Not surprisingly this enormous potential has resulted in at least three caspase 1 inhibitors entering clinical trials (VX-740, IDN-6556, and VX-765) in recent years.
Commercial Applications
  • Potential therapeutic for a broad range of autoimmune diseases
  • Potential therapeutic for a broad range of inflammatory diseases

Request More Info

Licensing Contact: